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1. Introduction 
Low dose radon therapy is a traditional treatment in Central and Eastern Europe typically 
applied to alleviate chronic pain derived from inflammatory and non-inflammatory 
disorders of the musculoskeletal system. Additionally it has also been reported to be 
effective for the treatment of chronic airway inflammation and inflammatory conditions of 
the skin.  
Radon (222Rn) is a radioactive alpha particle emitting inert gas, present in natural soil and 
water at several European, Japanese and American health resorts and is administered either 
transcutaneously by balneotherapy or per inhalationem by balneotherapy or per 
inhalationem by speleotherapy either at „cold“ ambient temperature of 20° to 23° C (RnT) or 
at „hot“ ambient temperatures between 37° and 41.5° C (RnHT). Speleotherapy is performed 
in curative caves and tunnels where radon emanation occurs due to the presence of uranium 
containing soil. Low dose 222Rn - balneotherapy is performed in bath tubs filled with 222Rn 
containing thermal water at a concentration typically found in the respective region but 
usually between 370 and 1600 Bq/L. Whereas 222Rn-containing water is typically applied at 
37.0° C, speleotherapeutic administration is performed either as RnT [1] or RnHT. The latter 
treatment regime is uniquely performed at the Gasteiner Heilstollen in Bad Gastein, Austria, 
which offers an average 222Rn concentration of 44000 Bq/m³ in a hyperthermic atmosphere 
between 37.0° and 41.5° C with high humidity between 70 and 100% that facilitates a mild 
increase of the body’s core-temperature of 0.5 - 1° Cdue to prevention of heat loss via 
evaporation confirmed by rectal measurement. A typical low-dose 222Rn-therapy consists of 
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nine to ten treatment units within a period of three weeks and an effective dose of 0.05 to 2 
mSv for balneotherapeutic and speleotherapeutic regimen, respectively [2]. 222Rn has a half-life 
of 3.8 days and decays via several short-lived daughters into the beta-emitting 210Plumbum 
with a half-life of 22.3 years. In general, radionuclide-based therapy has a long history in the 
management of rheumatic diseases and has been proven to alleviate pain and inflammation 
upon intraarticular or intravenous injection. Apart from conventional corticoid or cytostatic 
based therapy, radiosynoviorthesis is an alternative approach for the management of synovitis 
in course of chronic inflammatory arthropathies. The intraarticular injection of colloidal beta-
emitters, e.g. 90Yttrium, 186Rhenium or 169Erbium, lead to reduction of pain and joint swelling 
via abrogation of synovia hypertrophy by radiation-induced inhibition of the proliferative 
activity of synovial cells. The applied dose depends on the magnitude of the affected joint(s) 
and the severity of inflammation, whereas factors like intraarticular distribution of the 
radionuclide and thickness of the synovia dictate the absorbed dose. Therapeutic benefits in 
terms of pain and reduction of the inflammatory symptoms occur in 40 to 80% of the patients 
and manifest several months after therapy. However, numerous side effects like headache, 
fatigue, nausea and sometimes lymphedema, radiation-induced synovitis and periarticular 
necrosis due to aberrant injections have been reported [3]. 
Positive therapeutic effects of 224Radiumchloride-injections for patients suffering from 
ankylosing spondylitis were reported from Koch and Reske in 1952[4], after this therapy had 
been abolished due to the high incidence of malignant bone tumours and leukaemia in 
children and young adults previously treated for tuberculosis. Until now several studies 
have been conducted with a reduced dose regimen of 10 weekly injections with 1 MBq each 
resulting in an effective dose of 2.5 Sv [5] and a cumulative bone dose of 0.6 Gy [6]. The 
short-lived 224Radium has a half-life of 3.6 days and preferentially accumulates in the bone 
and in recently formed tissue calcifications when introduced into the body. In 2000 it was re-
approved in Germany by the German Federal Institute for Drugs and Medical Devices 
(Bundesinstitut für Arzneimittel und Medizinprodukte) as a pharmaceutical product for 
patients suffering from ankylosing spondylitis with stage II and III spinal ossification, 
provided that other therapy options had either failed or been contraindicated. However, 
recent findings clearly demonstrated an increased incidence of leukaemia and other 
malignant diseases in patients that were treated between 1948 and 1975 [6]. Despite the 
analgesic effects elicited by 224Radiumchloride-injections, the risk for malignant diseases 
exceeds the benefit and therefore, the committee for quality assurance of the German Society 
for Rheumatology no longer recommends this kind of therapy. Compared to a 222Rn-
speleotherapy regimen according to dosimetric calculations by Hofmann [7], the average 
dose to bone achieved by 224Radiumchloride injection regimen is approximately a factor 
3x105 higher. In contrast to the bone-seeking 224Radiumchlorid, inhalation of 222Rn and its 
daughters lead to a dose distribution that predominantly affects the bronchial epithelium in 
the upper tracheobronchial tree. When administered balneotherapeutically, diffusion of 
222Rn through the skin results in a uniform dose distribution throughout the organism [7]. To 
the best knowledge of the authors up to date no evidence points to an increased risk for the 
development of malignant diseases in context with RnHT [1, 2, 8].  
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Hyperthermia treatment (HT) has been reported to exert analgesic effects in rheumatoid 
disorders, to reduce systemic levels of the pro-inflammatory cytokines TNF-alpha, IL-1beta, 
and IL-6 [9, 10] and to accelerate the healing of sport injuries [11]. The postulated 
mechanisms include increased blood perfusion of the affected tissues and relaxation of 
muscle tissue. Given the fact, that combined RnHT or hyperthermia alone has been reported 
to alleviate pain in rheumatic conditions, presently, it cannot clearly be distinguished to 
which extent each of the active components – 222Rn and/or hyperthermia – are efficient for 
achieving the clinical-therapeutic benefits. According to empirical observations described 
below, these two agents may rather act in a synergistic manner.  
Apart from clinical observations, evidence from several controlled trials, one meta-analysis 
and numerous clinical observational studies further substantiate the beneficial effects of 
intermediate up to long term pain relief and functional improvement in patients suffering 
from rheumatic disorders of inflammatory or degenerative etiology. From a health economic 
point of view, cost effective therapies in the prevention or management of rheumatic 
diseases are of great importance since rheumatic disorders state a relevant cost factor due to 
the need for long term medication, frequent hospitalizations, joint arthroplasty and loss of 
productivity. The dramatically increasing proportion of aged individuals further aggravates 
the health economic issue of rheumatic diseases since at least the prevalence of non-
inflammatory, degenerative rheumatic disorders increases with progressing age [12].  
The long term intake of typically employed corticosteroids and non-steroidal anti-inflammatory 
drugs (NSAID) for the treatment of rheumatic disorders are reported to cause severe side effects 
that - apart from the primary disease - result in additional medical interventions and 
dramatically reduce the life quality of the affected individual. Some years ago, the mortality rate 
caused by gastrointestinal side effects due to NSAID intake was about 2000 per year in 
Germany [13] and 16.500 per year in the USA [14]. Despite the additional intake of gastro-
protective drugs, the ratio of NSAID-consumers suffering from gastrointestinal ulcers was 1 in 
400 and the ratio of those who died was 1 in 8000 [15]. The generation of cyclooxygenase-2 
inhibitors diminished the risk for gastrointestinal complications, however, the elevated risk for 
cardio-vascular events remained [16-18]. Taken together, from the patient´s as well as from the 
socio-economic point of view there is an urgent need for therapeutic strategies that allow either 
a reduction or discontinuation of medicament intake [19]. Combined RnHT can be regarded as 
a promising candidate in addressing these issues. Lind-Albrecht et al. demonstrated a long term 
reduction of analgesics during a 12-years follow-up in patients suffering from ankylosing 
spondylitis,  who regularly received combined RnHT [20]. 
A recently published meta-analysis including 338 patients suffering from rheumatic 
disorders showed a superior effect of combined RnHT compared to hyperthermia therapy 
in terms of pain reduction [21]. Although there was no difference between the treatment 
groups immediately after the therapeutic regimen, the group receiving the combination of 
222Rn and hyperthermia showed a significantly lower pain score during the three - and six - 
months follow-up. Prospective, randomized studies comparing the effect of combined RnTT 
with either HT or no treatment were included in the meta-analysis and are described along 
with more recently published findings in detail below.  
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Franke et. al demonstrated an intermediate to long term pain reduction in patients suffering 
from rheumatoid arthritis during a nine month follow-up after combined RnHT. This 
randomized, double-blinded study included 134 patients and compared the efficacy of 
balneotherapeutic regimen applied at 37° C either with or without 222Rn. Although both 
groups showed a beneficial effect immediately after therapy, the radon group predominated 
significantly at the three and six months follow up. Similar results were obtained concerning 
cut-down in NSAID and corticosteroid intake [22]. Consistent with these findings, a 
previous study including 60 patients with rheumatoid arthritis clearly demonstrated pain 
reduction and functional improvement of affected joints after a typical regimen of thermal 
water baths. However, patients receiving 222Rn thermal water showed a significantly 
pronounced effect on the analyzed parameters [23]. 
Van Tubergen et al. investigated in course of a randomized, controlled study the efficacy of 
speleotherapeutically applied RnHT combined with a complex rehabilitation program 
including gymnastics, hydro – and sport therapy. 120 patients suffering from ankylosing 
spondylitis were enrolled in the study and randomized in two treatment and one control 
group. Whereas the control group maintained its regular physiotherapeutic program at 
home, the intervention groups received the complex rehabilitation program either 
concomitantly with hyperthermia treatment in form of sauna regimen or concomitantly with 
speleotherapeutic combined RnHT. Bath Ankylosing Spondylitis Functional Index (BASFI), 
quality of life assessment score, pain score on a visual analogue scale and duration of 
morning stiffness were taken together to a Pooled Index of Change (PIC) as primary 
endpoint. Immediately after therapy both intervention groups showed a 20 to 30% 
improvement in contrast to the control group that remained unaffected. In the six to nine 
months follow up only the 222Rn group significantly prevailed [24, 25].  
In line with these results, Lind-Albrecht demonstrated a significant long-term pain 
reduction, improved mobility of the spine and reduced drug intake of patients with 
ankylosing spondylitis receiving a rehabilitation program combined with speleotherapeutic 
RnHT compared to those, who exclusively received the rehabilitation program [26, 27]. 
According to two double-blinded randomized studies by Pratzel et al., an intermediate-term 
pain reduction could be achieved by serially applied thermal water baths with or without 
222Rn in patients with non-inflammatory cervical syndrome and degenerative disorders of 
spine or joints, respectively. Immediately after therapy both treatment groups benefitted 
from an elevated threshold of pressure-provoked pain in the paravertebral muscles. A 
sustainable and significant pain reduction lasting until the two and four months follow-up 
could be demonstrated only in the 222Rn group [28, 29].  
A recent prospective study including 222 patients suffering from non-inflammatory, 
degenerative rheumatoid disorders investigated the sustainability of beneficial effects 
achieved by serially applied 222Rn containing thermal water baths. Compared to baseline 
levels, pain score and functional restriction of affected joints were significantly reduced up 
to twelve or six months, respectively. The fraction of patients with sickness absence was 
significantly reduced within one year after versus one year prior to therapy [30]. 
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Although the clinical benefit of combined RnHT has been investigated, to date little is 
known about the underlying cellular and molecular mechanisms of action. According to 
findings of Reinisch et al., suppression of the oxidative burst in neutrophil granulocytes of 
patients suffering of ankylosing spondylitis may be at least one key element explaining the 
therapeutic efficacy of speleotherapeutically applied combined RnHT. Reactive oxygen 
species (ROS) are released from activated phagocytes in course of inflammation and play a 
major role in tissue destruction in rheumatoid disorders. Neutrophil granulocytes isolated 
from peripheral blood of patients produced significantly less superoxide anions when 
restimulated ex vivo after a regimen of ten to twelve units of combined RnHT [31]. 
According to a previous study by Shehata et al., pain alleviation in ankylosing spondylitis 
correlates to an elevation in post-treatment serum levels of the anti-inflammatory cytokine 
TGF-beta [32]. 
Apart from its role as an immune-modulator, TGF-beta1 also plays a crucial role in bone 
homoeostasis, particularly by acting as differentiation factor for osteoclasts and via 
stimulation of osteoblast and downregulation of osteoclast activity [33]. TGF-beta1 exerts its 
effects in concert with other cytokines and hormones by influencing the 
OPG/RANKL/RANK system, which is crucial in the control of osteoblast and osteoclast 
interplay. Receptor activator of nuclear factor κB-ligand (RANKL) is a potent stimulator of 
osteoclast-mediated bone resorption and promotes osteolysis. It acts via binding to receptor 
activator of nuclear factor-κB (RANK) on osteoclasts. Osteoprotegerin (OPG) is the 
functional antagonist of RANKL as it acts as a soluble RANKL decoy receptor that, upon 
engagement with RANKL, abrogates the interaction with RANK and consequently inhibits 
maturation and activation of osteoclasts and their precursors. The relative concentrations of 
OPG and RANKL determine the status of bone metabolism and thus, the OPG/RANKL ratio 
has become an important marker to assess the prevailing metabolic bone turnover situation. 
An increased OPG/RANKL ratio indicates an anabolic and a decreased ratio a katabolic 
bone metabolism state. Chronic inflammatory processes give rise to increased bone 
resorption, which frequently results in secondary osteoporosis, a typical complication in 
rheumatic diseases. Moreover, osteoporosis is further aggravated by functional and pain-
related disuse bone atrophy and frequently employed glucocorticoid medication hence, 
predisposing the patient to a high risk of bone fracture [34]. In line with the results of 
Shehata et al. and the osteoimmunologic context explained above, a recently published pilot 
study confirmed the elevation of TGF-beta1 and demonstrated an increase of the 
OPG/RANKL ratio, thus indicating a shift of bone metabolism towards anabolic processes 
after speleotherapeutically applied RnHT [35, 36]. 
2. Conclusions 
Numerous studies have demonstrated a sustaining beneficial effect of combined low-dose 
RnHT when serially applied either by speleotherapy or balneotherapy to patients suffering 
from inflammatory or non-inflammatory degenerative disorders of the musculo-skeletal-
system. Of note, the most dominant effect is recognized several months rather than 
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immediately after therapy. Combined RnHT represents a cost effective method that 
alleviates pain and, thus, allows reducing drug intake which, in turn, may contribute to the 
prevention of adverse events caused by NSAIDs and glucocorticoids. As mentioned above, 
radionuclide-based therapy has been employed in the management of rheumatic disorders 
for decades. However, the poor benefit-risk ratio led to severe limitations or complete 
discontinuation in clinical use. RnHT poses doses to the patients which are in magnitude 10-
5 lower in respect to the bone dose compared to 224Radiumchloride-injection regimens. 
However, further studies are necessary to evaluate potential risks of low-dose RnHT. 
Although some studies implicate a beneficial effect of hyperthermia therapy for rheumatic 
diseases, combined RnHT turned out to be more effective than sauna or balneotherapy at an 
ambient temperature of 37° C lacking 222Rn. As combined RnHT may also exert beneficial 
effects in other disease entities, further studies are necessary to prove its place among the 
current treatment options.  
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